Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease
Abstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocomp...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical & Translational Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cti2.70038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839656172500549632 |
|---|---|
| author | Andrea S Henden Katie E Lineburg Archana Panikkar Arushi Mahajan Ricky Nelles Emma Wright Pauline Crooks Jyothy Raju Laetitia Le Texier Srividhya Swaminathan Leone Beagley Shannon Best Matthew Solomon Hilary Reddiex Glen Kennedy Siok‐Keen Tey Michelle A Neller Rajiv Khanna Corey Smith |
| author_facet | Andrea S Henden Katie E Lineburg Archana Panikkar Arushi Mahajan Ricky Nelles Emma Wright Pauline Crooks Jyothy Raju Laetitia Le Texier Srividhya Swaminathan Leone Beagley Shannon Best Matthew Solomon Hilary Reddiex Glen Kennedy Siok‐Keen Tey Michelle A Neller Rajiv Khanna Corey Smith |
| author_sort | Andrea S Henden |
| collection | DOAJ |
| description | Abstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocompromised patients. The objective of this study was to assess the safety of allogeneic virus‐specific T‐cell therapy in patients with COVID‐19. Methods Using a repository of SARS‐CoV‐2‐specific T cells generated from healthy exposed volunteers, we conducted an open‐label phase I trial to assess the feasibility and safety of allogeneic SARS‐CoV‐2‐specific T cells in immune‐compromised cancer patients with COVID‐19. Results Six participants at risk of severe COVID‐19 were enrolled and received SARS‐CoV‐2‐specific T‐cell therapy within 4 days of recruitment. The first five participants who received two infusions of allogeneic SARS‐CoV‐2‐specific T‐cell therapy experienced no adverse events following treatment. Four of the six participants showed improvement in viral load following treatment and were alive at 12‐week follow‐up. One participant died 6 days after their second infusion, because of established pulmonary parenchymal damage following prolonged COVID infection. Another, who had underlying lupus nephritis, developed cytokine release syndrome and diffuse alveolar haemorrhage following a single infusion and was withdrawn from the study. They subsequently recovered from this serious adverse event. Conclusion Allogeneic SARS‐CoV‐2‐specific T‐cell therapy provides a platform to rapidly administer T cells to high‐risk COVID‐19 patients. It was associated with a reduced viral load and increased SARS‐CoV‐2‐specific T‐cell responses in the majority of treated patients. |
| format | Article |
| id | doaj-art-d2e4bdec83c04fd38b3584b7ae96d381 |
| institution | Matheson Library |
| issn | 2050-0068 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical & Translational Immunology |
| spelling | doaj-art-d2e4bdec83c04fd38b3584b7ae96d3812025-06-24T23:08:44ZengWileyClinical & Translational Immunology2050-00682025-01-01146n/an/a10.1002/cti2.70038Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ diseaseAndrea S Henden0Katie E Lineburg1Archana Panikkar2Arushi Mahajan3Ricky Nelles4Emma Wright5Pauline Crooks6Jyothy Raju7Laetitia Le Texier8Srividhya Swaminathan9Leone Beagley10Shannon Best11Matthew Solomon12Hilary Reddiex13Glen Kennedy14Siok‐Keen Tey15Michelle A Neller16Rajiv Khanna17Corey Smith18Haematology and Bone Marrow Transplantation Unit Royal Brisbane and Women's Hospital Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaHaematology and Bone Marrow Transplantation Unit Royal Brisbane and Women's Hospital Herston QLD AustraliaHaematology and Bone Marrow Transplantation Unit Royal Brisbane and Women's Hospital Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaHaematology and Bone Marrow Transplantation Unit Royal Brisbane and Women's Hospital Herston QLD AustraliaHaematology and Bone Marrow Transplantation Unit Royal Brisbane and Women's Hospital Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaQueensland Immunology Research Centre, QIMR Berghofer Medical Research Institute Herston QLD AustraliaAbstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocompromised patients. The objective of this study was to assess the safety of allogeneic virus‐specific T‐cell therapy in patients with COVID‐19. Methods Using a repository of SARS‐CoV‐2‐specific T cells generated from healthy exposed volunteers, we conducted an open‐label phase I trial to assess the feasibility and safety of allogeneic SARS‐CoV‐2‐specific T cells in immune‐compromised cancer patients with COVID‐19. Results Six participants at risk of severe COVID‐19 were enrolled and received SARS‐CoV‐2‐specific T‐cell therapy within 4 days of recruitment. The first five participants who received two infusions of allogeneic SARS‐CoV‐2‐specific T‐cell therapy experienced no adverse events following treatment. Four of the six participants showed improvement in viral load following treatment and were alive at 12‐week follow‐up. One participant died 6 days after their second infusion, because of established pulmonary parenchymal damage following prolonged COVID infection. Another, who had underlying lupus nephritis, developed cytokine release syndrome and diffuse alveolar haemorrhage following a single infusion and was withdrawn from the study. They subsequently recovered from this serious adverse event. Conclusion Allogeneic SARS‐CoV‐2‐specific T‐cell therapy provides a platform to rapidly administer T cells to high‐risk COVID‐19 patients. It was associated with a reduced viral load and increased SARS‐CoV‐2‐specific T‐cell responses in the majority of treated patients.https://doi.org/10.1002/cti2.70038COVID‐19immunocompromisedSARS‐CoV‐2VST therapy |
| spellingShingle | Andrea S Henden Katie E Lineburg Archana Panikkar Arushi Mahajan Ricky Nelles Emma Wright Pauline Crooks Jyothy Raju Laetitia Le Texier Srividhya Swaminathan Leone Beagley Shannon Best Matthew Solomon Hilary Reddiex Glen Kennedy Siok‐Keen Tey Michelle A Neller Rajiv Khanna Corey Smith Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease Clinical & Translational Immunology COVID‐19 immunocompromised SARS‐CoV‐2 VST therapy |
| title | Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease |
| title_full | Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease |
| title_fullStr | Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease |
| title_full_unstemmed | Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease |
| title_short | Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease |
| title_sort | allogeneic off the shelf sars cov 2 specific adoptive t cell therapy for refractory viral infection and end organ disease |
| topic | COVID‐19 immunocompromised SARS‐CoV‐2 VST therapy |
| url | https://doi.org/10.1002/cti2.70038 |
| work_keys_str_mv | AT andreashenden allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT katieelineburg allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT archanapanikkar allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT arushimahajan allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT rickynelles allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT emmawright allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT paulinecrooks allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT jyothyraju allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT laetitialetexier allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT srividhyaswaminathan allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT leonebeagley allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT shannonbest allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT matthewsolomon allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT hilaryreddiex allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT glenkennedy allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT siokkeentey allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT michelleaneller allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT rajivkhanna allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease AT coreysmith allogeneicofftheshelfsarscov2specificadoptivetcelltherapyforrefractoryviralinfectionandendorgandisease |